In August 2013, Compugen entered into a collaboration and license agreement with Bayer for the research, development, and commercialization of immuno-oncology therapeutics against novel targets identified by Compugen. The companies collaborated to develop BAY 1905254, the lead antibody targeting ILDR2, a novel immune checkpoint target.

BAY 1905254 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors. The study, sponsored and conducted by Bayer, is an open-label, dose escalation study designed to evaluate the safety and tolerability of BAY 1905254. The study is evaluating BAY1905452 as monotherapy and in combination with Keytruda, with expansion cohorts in bladder, gastric, cervical and head & neck cancers (monotherapy or combination). For additional information on the Phase 1 study click here

Compugen has received over $30 million in upfront, preclinical and clinical milestone payments, and is eligible to receive over $250 million in total milestone payments, as well as tiered royalties on global sales.

“At Bayer HealthCare, we are impressed with Compugen’s ability to identify novel immune checkpoints through the use of their predictive discovery infrastructure, and are pleased to collaborate with their professional scientific team on therapeutic antibody development in the field of immuno-oncology.”
Karl Ziegelbauer, Head of Global Therapeutic Research Groups, Bayer


Max 1mb, accepted formats: pdf, doc, docx, rtf
[recaptcha size:compact]
Message Sent. Thank You!